Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Belle Health vs MyFastRx

Belle Health
Graded #48

Higher grade

vs+9.599999999999994
MyFastRx
Graded #172

Lower grade

The verdict

Belle Health takes it — 77/100 to 67.4/100.

Belle Health grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Belle Health is a national DTC telehealth platform offering compounded semaglutide and tirzepatide with flat-rate pricing — the same monthly cost at every dose, with no escalation surcharge as you titrate up.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueBelle Health +17
92
75
Dose & formulationEven
72
72
Clinical oversightBelle Health +5
71
66
Labs & monitoringBelle Health +20
72
52
FulfillmentBelle Health +2
85
83
Contract termsBelle Health +14
55
41
Belle Health · left barMyFastRx · right bar

The numbers

MetricBelle HealthMyFastRx
WeighScore77/10067.4/100
GradeC+C
Scorecard rank#48#172
Semaglutide$119/mo$169/mo
Tirzepatide$199/mo (all doses, 3-month plan, compounded)$249/mo
CoverageAll 50 statesAll 50 states
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyInjection only
Belle Health

Graded #48 · C+

Strengths

  • Five named compounding pharmacy partners disclosed (Striker, Strive, OptioRx, Enovex, Braun PharmaCare)
  • Flat-rate pricing — $119/mo semaglutide, $199/mo tirzepatide — doesn't rise at higher doses
  • Free weekly registered-dietitian sessions included
  • Operating since 2017
  • LegitScript Certified

Where it loses points

  • $199 tirzepatide price requires a 3-month bundle commitment
  • Compounded medications are not FDA-approved
  • Multi-pharmacy model — formulations may differ across orders
  • FDA issued this company a warning letter dated 20 February 2026; the letter is public in FDA's warning-letter database
MyFastRx

Graded #172 · C

Strengths

  • Aggressive 12-month bundle pricing — $99/mo semaglutide, $149/mo tirzepatide
  • LegitScript certified
  • All doses priced the same — no cost escalation as you titrate up
  • First-month promo discount lowers the trial barrier

Where it loses points

  • States served not disclosed — only 'multiple states' / 'licensed U.S. providers'
  • Corporate address and medical director not published
  • Pharmacy partner not named — only 'state-licensed pharmacies'
  • Cash-pay only — no insurance billing
  • Bundle savings require a large upfront commitment (12 months billed at once)

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard